Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...

The patient underwent treatment in December with Sarepta's therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys is the only FDA-approved gene therapy for Duchenne ...

Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...